免疫检查点抑制剂在乳腺癌免疫治疗中应用进展

Application progress of immune checkpoint inhibitor in immunotherapy of breast cancer

乳腺癌已成为全球发病率最高的癌症,其异质性使得乳腺癌分类治疗进入了精准治疗时代。随着肿瘤免疫治疗的成功,既往被认为“弱免疫原性”的乳腺癌也跨入了免疫治疗阶段。目前,免疫检查点抑制剂在乳腺癌免疫治疗的临床应用中取得了重大进展,但乳腺癌免疫治疗单药的获益人群有限,联合方案成为新的研究热点。随着免疫检查点抑制剂在乳腺癌中的研究进展,有效联合免疫治疗和化疗可能提高乳腺癌病人的生存率,但用药时机和适用人群仍需合理评估。免疫治疗在乳腺癌中既有应用前景,也存在挑战。

Breast cancer has become the most common cancer in the world,and its heterogeneity makes breast cancer classification therapy enter the era of precision treatment.With the success of immunotherapy,breast cancer which was previously considered as"weak immunogenicity"also has entered the stage of immunotherapy.At present,immune checkpoint inhibitors have made great progress in the treatment of breast cancer.But the population who benefit from immune monotherapy is limited,making the combined program a new research hotspot.With the research progress of immune checkpoint inhibitors in breast cancer,and it is suggested that combination immunotherapy and chemotherapy can improve the survival rate of breast cancer patients.But the timing and indications need to be strictly evaluated.Immunotherapy has both application prospects and challenges in breast cancer.